Are Tesco (LON:TSCO) and GlaxoSmithKline (LON:GSK) deep value investments?

Deep value fund Silchester has a major stake in several potential growth stocks including Tesco and GlaxoSmithKline. Are these tempting investments?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Last week private equity firm Clayton, Dubilier & Rice made an offer of £5.5bn to buy UK supermarket Morrisons. The company rejected it as being too low. But analysts expect a better offer in the coming weeks. The biggest shareholder in Morrisons is deep value fund Silchester. And the asset management fund is run by one of Britain’s wealthiest fund managers Stephen Butt. It’s highly likely to be up to him if a Morrisons takeover bid is accepted.

Butt is a philanthropist and paid himself at least £27m in 2019. Recent news shows he and his colleagues received a £110.8m payout for the latest financial year. Such a large payout as the pandemic continues puts Silchester under the spotlight after years of staying in the shadows.

Morrisons is not Silchester’s only deep value play

Yet, Silchester is not new to the scene and is a significant investor in several UK stocks with potential growth stories. These include GlaxoSmithKline (LSE:GSK), Mitie, Pearson, and Tesco (LSE:TSCO).  

So, as speculation continues, does Silchester have a keen eye for value?

I wrote about Tesco earlier in the week as I think its institutional investors will be meeting management in the coming weeks to encourage action that will benefit shareholders. Tesco is operating under new management, and investors are hopeful a dividend is in the offing.

But investors appear to be running out of patience. I imagine a management strategy, share buyback, or dividend, would go a long way to appeasing relations and improving the Tesco share price.

Tesco’s Q1 results were not outstanding, but they show resilience and signs of growth. E-commerce sales are high, generating 1.3m orders a week. Two-year sales growth came in over 81.6%, while one-year sales growth rose 22.2%. General merchandise sales rose 10.3%, and clothing sales are up 52.1%.

Considering Tesco shares are trading at the low end of analyst expectations, I think they look like a potential deep value investment.

Rise of the activists

With climate change, health initiatives, and political agendas ever-present, activist investor presence has a rising influence on the direction companies take.

Tesco is no stranger to investor activism. It already agreed to raise its sales of healthy foods to 65% by 2025, which Silchester didn’t oppose.

I don’t think investor activism is a bad thing. It can help steer the company in a customer-friendly direction while encouraging consumer loyalty and improving its ESG score.

I’m tempted to buy Tesco shares before its Q2 earnings call in October.

Interestingly, another of Silchester’s considerable holdings is GlaxoSmithKline, which just confirmed details of its consumer healthcare spin-off after months of speculation. This arm is expected to take some of the debt burdens from the leading company to focus on R&D.

GlaxoSmithKline has a Covid-19 vaccine in the works. But many believe it’s too little too late for the world’s top vaccine maker.

For this reason and a lack of profit-making in recent years, activist investor Elliot Advisors has been vocal lately. The firm suggests the group splits further.

I’ve found GlaxoSmithKline to be a disappointing investment. The GSK share price is down 2% in the past five years, despite a promising rise in 2019. For now, I’ll hold off on buying more shares. Time will tell if it’s a deep value investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline, Morrisons, Pearson, and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black colleagues high-fiving each other at work
Investing Articles

Is Legal & General Group one of the FTSE 100’s greatest value shares?

Legal & General shares boast low P/E ratios and massive dividend yields. Could they be one of the London stock…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

I’m looking for the best FTSE 100 value stocks to buy now. Have I found them?

Barclays, NatWest, and Imperial Brands shares are recovering strongly. But these FTSE 100 stocks still trade on rock-bottom earnings multiples.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Where on earth will Nio stock be in 1 year?

Nio stock has demonstrated extraordinary volatility over the past 12 months, but where will it be in a year's time?…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

6.9% dividend yield! 2 cheap stocks to consider for a £1,380 passive income

Looking for a market-beating passive income? These FTSE 100 and FTSE 250 dividend stocks could provide a healthy second income…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

Potentially 34% undervalued, should I be watching the boohoo share price?

The boohoo share price has seen a rocky few years, but with signs that the economy is improving, could this…

Read more »

Investing Articles

Is the Amazon share price primed for a drop?

The Amazon share price has been on a tear for the last year, but can this trend continue? Gordon Best…

Read more »

Photo of a man going through financial problems
Investing Articles

Down 15% in a week! What’s gone wrong with the National Grid share price?

The National Grid share price isn't supposed to crash but now it has. Harvey Jones is wondering whether to take…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Taylor Wimpey just paid me £158.78. I’m aiming to turn that into a £100k yearly second income

Harvey Jones says small, regular dividend payments can turn a few pounds into a mighty second income, if he gives…

Read more »